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 INTRODUCTION
 Hyperprolactinemia is an important but often a 
neglected side effect of antipsychotic treatment. 
Blockage of dopamine in the tuberoinfundibular 
dopamine system causes hyperprolactinemia1. 
Dopamine inhibits prolactin release by stimulating 
D2 receptors and serotonin induces prolactin 
r e l e a s e  b y  5 H T- 2 A  r e c e p t o r s.  A t y p i c a l 
antipsychotics do not effect dopamine blockage to 
the same extent as other antipsychotics in the 
tuberoinfundibular pathway, and inhibit prolactin 
release by mainly acting on serotonin by blocking 
5HT-2A receptors1-4.
 Aripiprazole is a partial agonist of presynaptic 
and postsynaptic dopamine D2 receptors and has 
a strong affinity for D3 receptors and moderate 
affinity for D4 receptors. It also acts as a partial 
agonist of serotonin 5HT-1A and 5HT-2C receptors, 
and an antagonist of 5HT-2A receptors. 
Consequently, it has been reported that the 
receptor binding profile of aripiprazole suggests 
efficacy on both positive and negative symptoms 
with a low risk of side effects, and it does not affect 
serum prolactin levels and it may even stabilize 
these levels5,6.
 In this case report, we present a female patient 
using antidepressants for depression with 
p s y c h o t i c  s y m p t o m s ,  w h o  d e v e l o p e d 
hyperprolactinemia when aripiprazole is added to 
the treatment and we discuss the effects of 
aripiprazole on serum prolactin levels.
ÖZET:
Aripiprazol ile hiperprolaktinemi: Olgu 
sunumu ve literatür derlemesi
Hiperprolaktinemi antipsikotik tedavinin önemli, fakat 
ihmal edilebilen bir yan etkisidir. Aripiprazol dopamin 
D2 reseptörleri üzerinde parsiyel agonist etkili ve düşük 
hiperprolaktinemik yan etkiye sahip atipik bir 
antipsikotiktir. Bu olgu bildiriminde, psikotik özellikli 
depresyon tanısı konan ve plazma prolaktin seviyesi 
aripiprazol ile tedavi edilirken yükselen bir kadın hasta 
sunuldu. Aripiprazolün prolaktin yüksekliği yapma 
riskinin daha düşük olduğu bildirilse de klinisyenler 
aripiprazolün ılımlı prolaktin yüksekliği yapabileceğini 
göz önünde bulundurmalıdır.
Anahtar sözcükler: aripiprazol, antipsikotik, 
hiperprolaktinemi, yan etki
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ABS TRACT:
Hyperprolactinemia with aripiprazole: 
a case report and review of the literature
Hyperprolactinemia is an important but often a 
neglected side effect of antipsychotic treatment. 
Aripiprazole is one of the new atypical antipsychotics 
that has partial agonist effects on dopamine D2 
receptors and has a low possibility of 
hyperprolactinemia. In the present case report, we 
discuss a female patient who was diagnosed as 
suffering from depression with psychotic symptoms. 
Her prolactin levels were elevated while on treatment 
with aripiprazole. Clinicians should consider that 
aripiprazole may result in moderate elevation of 
prolactin levels although it is reported that it has a 
lower risk of elevation of prolactin levels. 
Keywords: aripiprazole, antipsychotic, hyperprolactinemia, 
side effect
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 CASE REPORT
 A female patient, aged 21 years old, was referred 
to the psychiatry clinic with depressive complaints. 
She was diagnosed as having “major depressive 
disorder” according to the DSM-IV-R and sertraline 
50 mg/day was prescribed and she has used the 
drug for 9 months. During the follow-up period, 
visual, aural hallucinations and persecution 
delusions developed compatible with her mood. 
Finally, she was diagnosed with major depressive 
disorder with mood-congruent psychotic features 
according to the DSM-IV-R and aripiprazole 10 
mg/day was added to the treatment. During the 
follow-up period of 3 months; her depressive 
complaints were decreased and psychotic 
symptoms disappeared.
 By the third month of aripiprazole treatment, 
she had hirsutism, amenorrhea and galactorrhea 
complaints. It was also learnt that she was being 
followed-up at the gynecology clinic because of 
polycystic ovary syndrome which has been in 
remission for 18 months with no drug treatment. 
When her clinical records were examined, her 
serum prolactin level (16.09 ng/ml, normal ranges 
4-20 ng/ml) and testosterone level (74.9 ng/dl, 
normal ranges 0-80 ng/dl) were within normal 
ranges before aripiprazole treatment. Laboratory 
tests were repeated and her serum prolactin level 
was 27.14 ng/ml and testosterone level was 105 ng/
dl. The increased level of serum prolactin was 
thought to be related to aripiprazole by the 
gynecology clinic and the drug was discontinued. 
In the control visit one month after the drug 
discontinuance, serum prolactin (9.57 ng/ml) and 
testosterone (74.8 ng/dl) levels were found to be 
back to the normal levels and in the psychiatric 
examination, depressive symptoms were found to 
be increased and psychotic symptoms were found 
to have recurred. Thus, antidepressant treatment 
was continued and another atypical antipsychotic 
was prescribed.
 DISCUSSION
 Aripiprazole is known as a dopamine stabilizing 
agent. It has D2 receptor agonist and 5HT2A 
receptor antagonist properties. Based on these 
properties, it is reported that aripiprazole does not 
increase prolactin levels and may even decrease 
high prolactin levels associated with the use of 
other antipsychotics7,8. However, it has been 
reported that prolactin levels increased to 30 ng/ml 
and up to twice normal levels in two studies 
performed with rats given aripiprazole4,9. In these 
studies, high serum prolactin levels were 
interpreted as the mixed agonist/antagonist 
activity of aripiprazole on D2 receptors in lactotrop 
cells depending on the tonus of the existing 
dopaminergic neuronal activity. In other words, it 
was reported that the effect of aripiprazole resulted 
from its partial agonist property and its incomplete 
block of dopamine D2 receptors inhibiting 
prolactin release4.
 T h e r e  a r e  a  f e w  c a s e  r e p o r t s  o f 
hyperprolactinemia with aripiprazole. In the first 
report, a 36-year-old patient was receiving 
aripiprazole as monotherapy for schizophreniform 
Tab le 1: Cases of hyperprolactinemia occurred with aripiprazole treatment
No Authors Diagnosis Dose of aripiprazole Duration of Drugs simultaneously
    aripiprazole treatment used with aripiprazole
1 Mendhekar and schizophreniform 15 mg/day three weeks ____
 Andrade (2005) disorder
2 Ruffatti et al. (2005) schizoaffective 15 mg/day a few days haloperidol,
  disorder   sodium valproate,
     biperidene
3 Saraf et al. (2012) bipolar affective 15 mg/day three months lithium
  disorder 
4 Present case depression with 10 mg/day three months sertraline
  psychotic symptoms 
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disorder, and aripiprazole dosage was increased 
from 10 to 15 mg/day in 2 weeks. Breast tenderness 
and galactorrhea appeared in the third week10. In 
another case, it was reported that breast 
tenderness and galactorrhea appeared in a few 
days while  haloperidol  was tapered as 
recommended and aripiprazole 15 mg daily was 
introduced in a 29-year-old patient for 
schizoaffective disorder. The patient had also been 
treated with sodium valproate 1000 mg and 
biperidene 4 mg for many years11. In the last case, 
an 18-year-old patient was started on aripiprazole 
up to 15 mg/day with lithium 900 mg/day for 
bipolar affective disorder with a current episode of 
mania. On follow-up after 3 months, it was 
r e p o r t e d  t h a t  s h e  h a d  c o m p l a i n t s  o f 
oligomenorrhea and hyperprolactinemia12 (Table 
1).
 The current patient had been diagnosed with 
depression with psychotic symptoms and was 
receiving a combination of aripiprazole and 
sertraline treatment. Sertraline, which is a member 
of the antidepressant group of selective serotonin 
reuptake inhibitors (SSRI), increases serotonin 
release, leads to a decrease of 5HT2 receptors by 
desensitization of presynaptic 5HT-1A receptors 
and slightly blockades the reuptake of dopamine. 
Within this action profile, it has been reported that 
aripiprazole can cause hyperprolactinemia even if 
it is rare13. However, serum prolactin levels were 
normal while our patient was taking sertraline as 
m o n o t h e r a p y.  C o m p l a i n t s  d u e  t o 
hyperprolactinemia appeared when aripiprazole 
was added to the treatment.
 Aripiprazole daily doses (15 mg/day) in the 
aforementioned three literature cases were higher 
than the present case (10 mg/day). It is known that 
there is a linear relationship between the dose of 
aripiprazole and D2 receptor occupancy12. Hence, 
aripiprazole at lower doses has greater partial 
agonistic activity, and at higher doses, it possibly 
acts as a full D2 antagonist. Therefore, it is more 
likely that hyperprolactinemia would occur in the 
previous case reports rather than in our case. It is 
noteworthy that the present case was taking an 
antipsychotic drug for the first time and its dose 
was low.
 The patient has comorbid polycystic ovary 
syndrome and it may be a risk factor for hormonal 
dysregulation. However, the patient was regarded 
as being in remission for polycystic ovary 
syndrome at the end of the gynecology 
consultation. Although she tends to have hormonal 
d y s r e g u l a t i o n ,  i t  i s  t h o u g h t  t h a t  t h e 
hyperprolactinemia was caused by aripiprazole, 
because serum prolactin levels elevated with 
aripiprazole use and disappeared on drug 
discontinuance. Therefore, further investigation 
was not needed to rule out the other factors such 
as prolactinoma.
 Consequently, clinicians should consider that 
the use of aripiprazole might result in elevation of 
serum prolactin levels, especially in polypharmacy 
and in risky patients such as those suffering from 
hormonal dysregulation, even though it has been 
reported to have little risk of hyperprolactinemia.
References:
1. Altıntoprak AE, Erol A, Koturoglu G, Gönül AS. The 
effects of atypical antipsychotics on woman’s fertility and 
pregnancy: case report. Klinik Psikofarmakoloji Bulteni-
Bulletin of Clinical Psychopharmacology 2005;15(4):182-6 
(Turkish).
2. Haddad PM, Wieck A. Antipsychotic-induced 
hyperprolactinaemia: mechanisms, clinical features and 
management. Drugs 2004;64(20):2291-314. [CrossRef]
3. Petty RG. Prolactin and antipsychotic medications: 
mechanism of action. Schizophr Res  1999; 35 
(Suppl):S67-73. [CrossRef]
4. Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval 
M, Leduc N, et al. Partial agonist properties of the 
antipsychotics SSR181507, aripiprazole and bifeprunox at 
dopamine D2 receptors: G protein activation and prolactin 
release. Eur J Pharmacol 2006 27;535(1-3):135-44.
5. Kessler RM. Aripiprazole: what is the role of dopamine D(2) 
receptor partial agonism? Am J Psychiatry 2007;164(9):1310-
2. [CrossRef]
6. Monkul ES, Akdede BB. Aripiprazole: A new atypical 
antipsyhotic drug. Klinik Psikofarmakoloji Bulteni-Bulletin 
of Clinical Psychopharmacology 2005;15(4):198-203 
(Turkish).
260 Klinik Psikofarmakoloji Bülteni, Cilt: 24, Sayı: 3, 2014 / Bulletin of Clinical Psychopharmacology, Vol: 24, N.: 3, 2014 - www.psikofarmakoloji.org
Hyperprolactinemia with aripiprazole: a case report and review of the literature
7. Lieberman JA. Dopamine partial agonists: a new class of 
antipsychotic. CNS Drugs 2004;18(4):251-67. [CrossRef]
8. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH 
et al. Adjunctive treatment with a dopamine partial 
agonist, aripiprazole, for antipsychotic-induced 
hyperprolactinemia: a placebo-controlled trial. Am J 
Psychiatry 2007;164(9):1404-10. [CrossRef]
9. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the 
novel antipsychotic agent 7(4-[4-(2,3-dichlorophenyl)–1-
piperazinyl]butyloxy)-3,4-dihydro–2(1H)–quinolinone 
(OPC-14597) on prolactin release from the rat anterior 
pituitary gland. J Pharmacol Exp Ther 1996;277(1):137-43.
10. Mendhekar DN, Andrade C. Galactorrhea with aripiprazole. 
Can J Psychiatry 2005 ;50(4):243.
11. Ruffatti A, Minervini L, Romano M, Sonino N. Galactorrhea 
with aripiprazole. Psychother Psychosom 2005;74(6):391-2. 
[CrossRef]
12. Saraf G, Behere RV, Venkatasubramanian G, Rao NP, 
Varambally S, Gangadhar BN. Hyperprolactinemia with 
Aripiprazole: Understanding the Paradox. Am J Ther 
2014;21(3):e80-1. [CrossRef]
13. Nebhinani N. Sertraline-induced galactorrhea: case report 
and review of cases reported with other SSRIs. Gen Hosp 
Psychiatry 2013;35(5):576. [CrossRef]
